Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib with Cisplatin and Etoposide in Extensive Stage Small Cell Lung Cancer
NCT01642251Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2012
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) comparing Arm A (veliparib) with Arm B (placebo) (2 arms). Primary endpoints: Recommended Phase II Dose at cycle 1 and Progression-Free Survival. Started Sep 2012; status: completed.
02
Drugs
veliparib
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01642251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01642251.